IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression
This study has been withdrawn prior to enrollment.
(never initiated, did different study)
Sponsor:
University of Alabama at Birmingham
Information provided by (Responsible Party):
Cheryl McCullumsmith, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01770600
First received: August 7, 2012
Last updated: May 26, 2015
Last verified: May 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care.
| Condition | Intervention |
|---|---|
| Impulsivity Active Suicidal Ideation Depression | Other: placebo Drug: Riperidone |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Participant) Primary Purpose: Treatment |
| Official Title: | Assessment and Treatment of Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression. |
Resource links provided by NLM:
Further study details as provided by Cheryl McCullumsmith, University of Alabama at Birmingham:
Primary Outcome Measures:
- Decrease in depression symptoms [ Time Frame: baseline to 5 days ]
| Enrollment: | 0 |
| Study Start Date: | April 2010 |
| Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Risperidone
Administer pill of risperidone 1 mg once a day by mouth for 5 days.
|
Drug: Riperidone
1 mg risperidone administered orally for 5 days
Other Name: risperdal
|
|
Placebo Comparator: Placebo
Administer pill of placebo once a day by mouth for 5 days.
|
Other: placebo
placebo pill administered daily for 5 days
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 19 Years to 64 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age : 19-64
- Suicidality score of > 4 on Montgomery-Asberg Depression Rating Scale (MADRS)
Exclusion Criteria:
- pregnant,
- medically unstable,
- history of schizophrenia,
- schizoaffective disorder,
- bipolar disorder,
- psychosis NOS,
- urine drug screen positive for cocaine,
- marijuana or amphetamines,
- withdrawal from opiates,
- benzodiazepines or alcohol,
- currently on antipsychotic drug therapy. Also excluded are those subjects who require the use of mood stabilizers or antipsychotics.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01770600
Please refer to this study by its ClinicalTrials.gov identifier: NCT01770600
Locations
| United States, Alabama | |
| University of Alabama Birmingham | |
| Birmingham, Alabama, United States, 35294 | |
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
| Principal Investigator: | Cheryl B McCullumsmith, MD PhD | University of Alabama at Birmingham |
More Information
| Responsible Party: | Cheryl McCullumsmith, Division Director, Hospital Psychiatry, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT01770600 History of Changes |
| Other Study ID Numbers: |
F1003310002 |
| Study First Received: | August 7, 2012 |
| Last Updated: | May 26, 2015 |
Keywords provided by Cheryl McCullumsmith, University of Alabama at Birmingham:
|
Age 19 to 64 Medically stable No current or history of psychosis No alcohol or benzodiazepine withdrawal |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Suicidal Ideation Impulsive Behavior Behavioral Symptoms Mood Disorders Mental Disorders Suicide Self-Injurious Behavior Risperidone Serotonin Antagonists |
Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents |
ClinicalTrials.gov processed this record on July 21, 2017